You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
More potent than either GABA or muscimol as an agonist at low affinity GABAA receptors and is thus a useful ligand to investigate GABA receptors linked to benzodiazepine receptors. Also a GABAA-ρ receptor antagonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 10 mM in water|
References are publications that support the biological activity of the product.
Allan et al (1986) Isothiouronium compounds as γ-aminobutyric acid agonists. Br.J.Pharmacol. 88 379 PMID: 3015310
Holden-Dye and Walker (1988) ZAPA, (Z)-3-[(aminoiminomethyl)thio]-2-propenoic acid hydrochloride, a potent agonist at GABA-receptors on the Ascaris muscle cell. Br.J.Pharmacol. 95 3 PMID: 2851353
Johnston (1996) GABAC receptors: relatively simple transmitter-gated ion channels? TiPS 17 319 PMID: 8885697
If you know of a relevant reference for ZAPA sulfate, please let us know.
View Related Products by Product Action
Keywords: ZAPA sulfate, ZAPA sulfate supplier, GABAC, antagonists, agonists, low, affinity, GABAA, receptors, Receptors, GABAA-rho, 0180, Tocris Bioscience
1 Citation for ZAPA sulfate
Citations are publications that use Tocris products. Selected citations for ZAPA sulfate include:
Asiedu et al (2012) Modulation of spinal GABAergic analgesia by inhibition of chloride extrusion capacity in mice. J Pain 13 546 PMID: 22537560
Do you know of a great paper that uses ZAPA sulfate from Tocris? Please let us know.
Reviews for ZAPA sulfate
There are currently no reviews for this product. Be the first to review ZAPA sulfate and earn rewards!
Have you used ZAPA sulfate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.